With an increasing number of COVID-19 vaccines becoming available, the end of the pandemic is now in sight, but even with efforts to scale up production the supply of vaccines will influence the speed of vaccination. As a result, careful vaccine allocation is needed to maximize social and economic benefits across the U.S. Multiple frameworks have recently been developed to guide vaccine allocation, including one led by our team at CRA and the Center for Global Health Innovation (CGHI) Vaccine Economics and Equity Group (VEEG).1 As we discuss in PM360, this new framework offers guidelines for COVID-19 vaccine allocation under conditions of scarcity that considers core public health and ethical principles in the context of optimal benefit to the U.S. economy.
Funding innovation under pressure: examining the role of commercial health insurance in Europe
Europe’s health systems are facing growing pressure amidst strained public budgets, ageing populations, and increasing treatment costs, prompting urgent questio